Suppr超能文献

眼表疾病和泪液生物标志物:眼部过敏和干眼症的诊断和临床观察。

Tear and ocular surface disease biomarkers: A diagnostic and clinical perspective for ocular allergies and dry eye disease.

机构信息

Department of Research, Development and Innovation, Faes Farma, Bizkaia, Spain.

Pharmacy Department, University of Navarra, Navarra, Spain.

出版信息

Exp Eye Res. 2022 Aug;221:109121. doi: 10.1016/j.exer.2022.109121. Epub 2022 May 21.

Abstract

Validated biomarkers to be used as biological tools for managing ocular surface diseases (OSDs) are still an unmet need in daily clinical practice. Many studies have contributed to the already extensive list of candidate biomarkers for these disorders. Dry eye (DE) and ocular allergy (OA) are complex and multifactorial diseases, often coexisting and with overlapping symptoms. The purpose of this review is to present a comprehensive updated revision of the most relevant biomarkers of DE and OA, with an emphasis on quantitative analyses and correlations with clinical parameter data. Analysis of biomarkers common for these pathologies has highlighted an important physiological process. Namely, the interleukin proteins (IL-1α, IL-1β and IL-17), tumour necrotic factor (TNFα) and interferon gamma (IFNγ; Th1-Th7 pathway) and IL-4, IL-5 and IL-13 (Th2 pathway) seem to represent similar inflammatory mechanisms. Moreover, changes in the levels of mucins (MUC1, MUC2, MUC4, MUC5 and MUC16) are common alterations in the tear film mucous layer. We also examine the current state of medical devices and the main limitations to their use in clinical practice. Translational research in biomarkers for clinical practice depends on a feasible transition from the laboratory to the point-of-care. This requires large-scale, coordinated clinical validation campaigns to select the biomarkers with the highest specificity and sensitivity and significant correlation with clinical parameters. Moreover, technical limitations of multiplexed quantitation systems must be overcome to detect and measure the levels of several biomarkers in very small samples. To ensure the future of biomarker research, significant progress is necessary in a number of fields. There is an urgent need for global unification of clinical classification and diagnostics criteria. Widespread integration of proteomic and transcriptomic data is paramount for performing meaningful analyses using appropriate bioinformatics tools and artificial intelligence systems.

摘要

用于管理眼表疾病(OSD)的经过验证的生物标志物仍然是日常临床实践中的未满足需求。许多研究为这些疾病的候选生物标志物已经很广泛的列表做出了贡献。干眼症(DE)和眼过敏(OA)是复杂的多因素疾病,经常并存且症状重叠。本综述的目的是全面更新和修订 DE 和 OA 的最相关生物标志物,重点是定量分析和与临床参数数据的相关性。对这些病理的生物标志物的分析突出了一个重要的生理过程。即白细胞介素蛋白(IL-1α、IL-1β 和 IL-17)、肿瘤坏死因子(TNFα)和干扰素γ(IFNγ;Th1-Th7 途径)和 IL-4、IL-5 和 IL-13(Th2 途径)似乎代表了类似的炎症机制。此外,粘蛋白(MUC1、MUC2、MUC4、MUC5 和 MUC16)水平的变化是泪膜粘液层的常见变化。我们还检查了医疗器械的现状以及在临床实践中使用它们的主要限制。生物标志物的转化研究取决于从实验室到床边的可行过渡。这需要大规模、协调的临床验证活动来选择具有最高特异性和灵敏度以及与临床参数显著相关性的生物标志物。此外,必须克服多重定量系统的技术限制,以检测和测量非常小样本中的几种生物标志物的水平。为了确保生物标志物研究的未来,许多领域都需要取得重大进展。迫切需要全球统一临床分类和诊断标准。广泛整合蛋白质组学和转录组学数据对于使用适当的生物信息学工具和人工智能系统进行有意义的分析至关重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验